SETD1A抗体;SETD1A Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13597(SETD1A Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The SETD1A antibody is a crucial tool in epigenetics research, targeting the SETD1A (SET Domain Containing 1A) protein, a histone methyltransferase responsible for catalyzing mono-, di-, and trimethylation of histone H3 at lysine 4 (H3K4me). This post-translational modification is associated with active gene transcription, playing a pivotal role in chromatin remodeling and transcriptional regulation. SETD1A, a component of the COMPASS (Complex Proteins Associated with Set1) family, is essential for embryonic development, stem cell differentiation, and cellular identity maintenance. Dysregulation of SETD1A has been linked to cancers, neurodevelopmental disorders, and cardiovascular diseases, driving interest in its functional analysis.

The antibody enables detection and localization of SETD1A in techniques like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP). Researchers prioritize antibodies validated for specificity (e.g., knockout cell line controls), cross-reactivity, and performance across species (human, mouse, rat). Commercial SETD1A antibodies are typically raised against epitopes in the N-terminal or C-terminal regions, with host species including rabbit, mouse, or goat. Applications extend to studying SETD1A’s role in DNA repair, cell cycle regulation, and its interaction with other chromatin modifiers. Challenges include distinguishing SETD1A from homologous family members (e.g., SETD1B) and ensuring consistent activity in diverse experimental conditions. Proper validation using siRNA knockdown or CRISPR-Cas9 models is critical to avoid off-target artifacts, ensuring reliable data in both basic and translational research contexts.